Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18680102 | 0.88 | KDM4E (0.35) | CA1CA2POLBALDH1A1KDM4E | |
| SCHEMBL3290567 | 0.79 | ELANE (0.43) | CA1CA2BCHEACHEPOLB | |
| SCHEMBL17038536 | 0.78 | INPPL1 (0.44) | ALDH1A1KDM4E | |
| SCHEMBL11587100 | 0.73 | CA1 (0.35) | CA1CA2BCHEACHEPOLB | |
| SCHEMBL3225021 | 0.72 | LMNA (0.55) | CA1CA2BCHEACHEPOLB | |
| SCHEMBL31634474 | 0.72 | KCNK3 (0.43) | CA1CA2BCHEACHEALDH1A1 | |
| SCHEMBL3380900 | 0.71 | MEN1 (0.40) | CA1CA2BCHEACHEPOLB | |
| SCHEMBL17355869 | 0.71 | KMT2A (0.37) | CA1CA2BCHEACHEPOLB | |
| SCHEMBL20703842 | 0.71 | MEN1 (0.47) | CA1CA2BCHEACHEPOLB | |
| SCHEMBL27453980 | 0.71 | CA1 (0.48) | CA1CA2BCHEACHEPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018174-A1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | VENTANA MED SYST INC (US) | 2024-01-18 | — | — | US | disclosed |
| US-11780863-B2 | Quinone methide analog signal amplification | VENTANA MEDICAL SYSTEMS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11365210-B2 | Quinone methide analog signal amplification | VENTANA MEDICAL SYSTEMS, INC. (US) | 2022-06-21 | — | — | US | disclosed |
| EP-3492919-A2 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | Ventana Medical Systems, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20190127405-A1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | VENTANA MED SYST INC (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190128893-A1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | VENTANA MED SYST INC (US) | 2019-05-02 | — | — | US | disclosed |
| US-10168336-B2 | Quinone methide analog signal amplification | VENTANA MEDICAL SYSTEMS, INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-20170089911-A1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | VENTANA MEDICAL SYSTEMS, INC. | 2017-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190128893-A1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | NQO2, SQOR, MRM1 | CA1 1613/4885CA2 2563/4885BCHE 276/4885 |
| US-20190127405-A1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | NQO2, SQOR, MRM1 | CA1 1613/4885CA2 2563/4885BCHE 276/4885 |
| US-11780863-B2 | Quinone methide analog signal amplification | NQO2, SQOR, MRM1 | CA1 1613/4885CA2 2563/4885BCHE 276/4885 |
| US-20240018174-A1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | NQO2, SQOR, MRM1 | CA1 1613/4885CA2 2563/4885BCHE 276/4885 |
| US-20170089911-A1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | NQO2, SQOR, MRM1 | CA1 1613/4885CA2 2563/4885BCHE 276/4885 |
| US-10168336-B2 | Quinone methide analog signal amplification | NQO2, SQOR, MRM1 | CA1 1613/4885CA2 2563/4885BCHE 276/4885 |
| US-11365210-B2 | Quinone methide analog signal amplification | NQO2, SQOR, MRM1 | CA1 1613/4885CA2 2563/4885BCHE 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.